(1) The revenue attributable to all intellectual property rights and other commercial rights arising from the drug development clinical trial conducted by a consortium under this act during the period for which the trial is funded and any following period of commercialization shall be allocated as follows:(a) Not less than twenty percent (20%) to the state as specified in the contract under Section 41-155-13, which shall be deposited into the State General Fund; and(b) The remainder to the members of the consortium in the amounts specified by written agreement of the members.
(a) Not less than twenty percent (20%) to the state as specified in the contract under Section 41-155-13, which shall be deposited into the State General Fund; and
(b) The remainder to the members of the consortium in the amounts specified by written agreement of the members.
(2) For purposes of this section, intellectual property rights and other commercial rights arising from the drug development clinical trial conducted under this chapter include any of the following as related to the trial:(a) Intellectual property, technology, and inventions;(b) Patents, trademarks, and licenses;(c) Proprietary and confidential information;(d) Trade secrets, data, and databases;(e) Tools, methods, and processes;(f) Treatment models or techniques;(g) Administration protocols; and(h) Works of authorship.
(a) Intellectual property, technology, and inventions;
(b) Patents, trademarks, and licenses;
(c) Proprietary and confidential information;
(d) Trade secrets, data, and databases;
(e) Tools, methods, and processes;
(f) Treatment models or techniques;
(g) Administration protocols; and
(h) Works of authorship.